U.S. Markets closed

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.49-0.14 (-1.62%)
At close: 4:00PM EDT
8.49 0.00 (0.00%)
After hours: 04:43PM EDT

Poseida Therapeutics, Inc.

9390 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 779 3100
http://www.poseida.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees208

Key Executives

NameTitlePayExercisedYear Born
Dr. Eric M. OstertagCEO & Director858.68kN/A1973
Mr. Mark J. GergenPres, Chief Bus. Officer & Director636.49kN/A1963
Mr. Harry J. LeonhardtGen. Counsel, Chief Compliance Officer & Corp. Sec.494.54kN/A1957
Ms. Johanna M. Mylet CPASr. VP of Fin.N/AN/A1987
Mr. Kerry D. IngallsChief Operating OfficerN/AN/A1962
Sarah ThailingDirector of Corp. Communications & IRN/AN/AN/A
Ms. Kristin MartinChief HR OfficerN/AN/AN/A
Dr. Devon J. ShedlockSr. VP of R&DN/AN/AN/A
Dr. Matthew A. SpearChief Medical OfficerN/AN/A1967
Mr. Jeff KnightSr. VP of Portfolio Management & Corp. OperationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California.

Corporate Governance

Poseida Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.